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INTRODUCTION 
Dry eye is a complex condition with an inflammatory component, characterised by changes to the 
ocular surface which relate to increased tear osmolarity and a reduced quantity or quality of tears. 
The Dry Eye Workshop (DEWS) defined dry eye as ‘a multifactorial disease of the tears and ocular 
surface that results in symptoms of discomfort, visual disturbance, and tear film instability with 
potential damage to the ocular surface, accompanied by increased osmolarity of the tear film and 
inflammation of the ocular surface.’ The key additions to their 1995 definition were the inclusion of 
symptoms of visual disturbance, osmolarity and inflammation [1, 2]. The average tear film thickness 
has recently been estimated at 3µm [3], which if reduced, can result in symptoms of discomfort, 
changes in corneal sensitivity and a reduction of visual quality [1], where local variations in power 
produce higher order aberrations and  degradation of the image [4, 5].  
Changes in tear osmolarity can be measured by tests such as the TearLab system (Ocusense Inc., San 
Diego, CA, US), although the symptoms of discomfort can also be assessed subjectively by 
questionnaire or history and symptoms [1]. Sodium fluorescein is widely referred to as a ‘vital dye,’ 
although this is has been challenged as the mechanism of staining is not fully understood [6]. 
Standardized grading of corneal and conjunctival fluorescein staining have given this dye broad 
applicability as a dry-eye diagnostic test, particularly as an assessment tool in clinical studies of dry 
eye. Nichols reported retrospectively on a group of 447 patients with dry eye in a clinic based sample 
and found symptom assessment (82.8%), fluorescein staining (55.5%) and tear break up time 
(40.7%) to be the most frequently used tests in cases with a dry eye diagnosis [7].  
Symptoms of dry eye are often exacerbated by environmental conditions e.g. low humidity [8] and 
tasks requiring concentration, e.g. computer use [9, 10]. The importance of symptoms is underlined 
by their inclusion in the definition of dry eye [1]; however, lack of correlation between signs and 
symptoms of dry eye limits the usefulness of data obtained in this way to assess severity [11-13]. 
Validated questionnaires have been used successfully as a method of screening for potential dry eye 
[14]. 
Artificial tears are the first line treatment for dry eye, but the exact mechanism of these products is 
difficult to identify as these preparations do not recreate the function of the tear film, but do seem 
to have a lubrication effect [15]. Preservatives in artificial tears have been shown to be detrimental 
to the ocular surface e.g. short term exposure to benzalkonium chloride has been shown to decrease 
goblet cell density in humans [16] and cause tear film instability [17], conjunctival squamous 
metaplasia and apoptosis [18], disruption of the corneal epithelium barrier [19], and have possible 
proinflammatory effects [20]. Unpreserved drops or alternative, less toxic preservatives are 
therefore preferable for the treatment of dry eye. Liposome sprays have been shown to increase 
lipid layer thickness and improve tear film stability in normal eyes for approximately 60 minutes 
following application to a closed eye [21]. The delivery system offers an advantage in that it does not 
require preservatives and is easy to apply. A reduction in aqueous volume has been shown to affect 
the spreading ability and stability of the lipid layer [22], introducing the possibility that a lubricant 
drop could theoretically enhance the performance of a lipid spray in dry eyes. 
Historically, the use of invasive techniques to evaluate the tear film may have compromised the 
results, which has led to the recommendation of ‘minimally invasive techniques’ for the diagnosis 
and monitoring of dry eye [14, 23].  The use of wavefront sensing aberrometers has been shown to 
be suitable for evaluating the optical qualities of the tear film [24] and assessing the effects of 
artificial tears [25].  
The purpose of this study was to examine the immediate effects of unpreserved hypromellose 0.3% 
w/v artificial tears (Lumecare®, Medicom Healthcare Ltd, Hampshire,UK) a liposome spray (Tears 
Again®, Optima Pharmazeutische GmbH) and the treatments combined, on patient-reported ocular 
comfort, higher order aberrations and Strehl ratio in normal and self-diagnosed dry eye subjects. 
METHODS 
Subjects 
The study was approved by the institutional ethics committee and the research followed the tenets 
of the Declaration of Helsinki. The nature of the study was explained to the participants and written, 
informed consent was obtained. A group of 24 normals (12 female, 12 male) with a mean age of 24.2 
(SD 8, median 21) years and dry eye subjects (15 female, 9 male) with a mean age of 25.7 (SD 7, 
median 22) years were recruited. The inclusion criterion for dry eye was a score of ≥6 according to 
the Chalmers 5-item questionnaire [26]. The mean dry eye questionnaire score for the normal group 
was 2.7 (median 2, SD 2.3). The mean dry eye questionnaire score for the dry group was 10.7 
(median 12, SD 3.2) (FIGURE 1). The exclusion criteria were: diagnosis of dry eye or any eye disease 
including ocular allergy, medication affecting the ocular surface, refractive surgery, contact lens 
wear and use of any eye drops within 24 hours prior to the study. 
The measurements were conducted in a stable, air-conditioned environment of 21° and 24% 
humidity. Subjects remained in this environment between measurements, during which time they 
performed tasks requiring high levels of concentration. 
Methods 
The subjects were assessed for all interventions administered to the right eye only on three different 
days within a two week period. The interventions were one drop of unpreserved hypromellose, one 
spray of liposome solution and the drop and spray combined. Unpreserved drops were selected as 
common preservatives e.g. benzalkonium chloride have a detergent effect [27] and the potential 
effect of this detergent on the liposome spray was unknown. Allocation of treatment order was 
decided for each subject using randomisation tables. Comfort levels for the right eyes were rated on 
a scale of 1-10, where 10 represented the most comfortable at baseline and after 1 hour. The 
subjects were seated with their chin on the chin-rest of the aberrometer when all lubricants were 
applied to enable the investigator to measure aberrations 5 seconds after intervention.  
Aberrometry was performed 2 seconds after a blink (aberrations are stable for up to 4s after a 
blink[28]) at baseline, 5 seconds after treatment and 1 hour after treatment using the Nidek OPD-
Scan III, an aberrometer/corneal topography workstation. The aberrometer works on the principle of 
scanning slit retinoscopy/skiascopy, measuring the time delay between the central and peripheral 
fundus reflexes. The difference in power across the pupil is used to generate the wavefront and 
autorefraction data [29] from which Zernike-based maps can be derived. The total eye wavefront 
error, total spherical aberration and total coma-like aberrations were recorded over a pupil diameter 
of 5mm, as this was the smallest natural pupil size in this cohort. Coma and spherical aberrations 
have been shown to be the most significant higher-order aberrations [30]. Magnitudes of the 
coefficients of Zernike polynomials were represented as the root mean square (RMS, in 
micrometers). The Strehl ratio for higher order aberrations was also recorded as a predictor of the 
image optical quality at the fovea, higher values indicating improved image quality [31]. A slit-lamp 
examination was performed after the final aberrometry reading to assess corneal staining using 
fluorescein sodium. The hypothesis for this study was that the combination of aqueous drops and a 
liposomal spray would result in the most stable and improved optical surface in the dry eye group 
after 60 minutes. The normal group was expected to exhibit minimal change after 60 minutes. 
 
Data analysis 
The Power calculation was conducted using G*Power 3.1 [32] (ANOVA repeated measures within 
factor) and 24 subjects were recruited to achieve a medium effect with 80% power and an alpha 
level of 0.05. Statistical analysis was performed with SPSS v20.0 (SPSS INC., Chicago, USA). The 
ranked data was analysed using Friedman’s ANOVA, with post hoc Bonferroni corrected Wilcoxon 
signed-rank tests. Normally distributed continuous data underwent parametric statistical analysis. 
Normality was confirmed for the data sets using Kolmogarov-Smirnoff. Analysis of variance (ANOVA) 
or 2 tailed independent t-tests were used to analyse the data. When ANOVA results were significant, 
post hoc Bonferroni corrected t-tests were used to control for type 1 error. A P value less than 0.05 
was considered significant.   
 
RESULTS 
The comfort scores revealed the largest improvement after the combination treatment; 2 (2) = 
6.240 p = 0.04 (Mean improvement in normal eyes 0.7 ± 0.2 and dry eyes 1.4 ± 1.1), followed by 
spray (Mean improvement in normal eyes 0.6 ± 0.2 and dry eyes 1.3 ± 1.3) then drops (Mean 
improvement in normal eyes 0.4 ± 0.2 and dry eyes 1.2 ± 1.1). The scores had larger standard 
deviations in the dry group, although post hoc comparisons between specific interventions and eye 
types did not reach statistical significance and the comfort scores did not support the treatment 
preferences (Fig.1 and table 1) 
The baseline total higher order aberrations, coma and spherical aberrations between the normal and 
dry groups were investigated to determine if there was a change in values across the visits before 
any intervention. The mean values for total higher order aberrations were slightly higher in the dry 
group; however, the standard deviations were large and this did not reach statistical significance on 
any separate occasion (Table 2).  
A mixed ANOVA model (eye type X time of measurement) was designed to determine whether the 
Strehl ratio for higher order aberrations showed a reduction by similar amounts in normal and dry 
eyes at each measurement time point. Table 3 shows the objective values and standard deviations 
for normal and dry eyes at baseline and 60 minutes after intervention.  For the hypromellose drops 
there was a significant main effect for the time of measurement, F (2, 92) = 9.91, p = <0.01; 
Bonferroni corrected post hoc tests showed this related to the change from baseline to immediately 
after instillation of hypromellose drops (mean difference in normal eyes 0.130, p = <0.01; mean 
difference in dry eyes 0.036, p = 0.01), however there was no significant difference between 
measurements taken at baseline and an hour after intervention in either eye type. For liposome 
spray there was no significant effect for time of measurement, F (2, 92) = 1.905, p = 0.155 or eye 
type, F (1, 46) = 1.839, p = 0.182. For hypromellose drops and liposome spray combined there was 
no significant effect for time of measurement F (2, 92) = 0.529, p = 0.591, or eye type F (1, 46) = 
0.911, p = 0.354. 
 Instillation of hypromellose drops increased total aberrations (F (1.36, 62.61) = 19.00, p<0.01, 
Greenhouse-Geisser corrected) from the ‘baseline’ compared with ‘immediately after’ (mean 
difference 0.23, p<0.01 for normal and dry eyes) and there was a similar sized reduction at the 
‘immediately after’ compared with ‘hour’ time points (mean difference 0.22, p<0.01 for normal and 
dry eyes). There was no significant effect for eyetype, F (1, 46) = 1.782, p = 0.188. Analysis for the 
effect of liposome spray on total aberrations showed no significant effect for time of measurement, 
F (2, 92) = 1.756, p = 0.178 or eye type, F (1, 46) = 3.060, p = 0.087. For drops and spray there was no 
significant effect for time of measurement F (2, 92) = 4.387, p = 0.15, or eye type F (1, 46) = 1.118, p 
= 0.296. 
Instillation of hypromellose drops had no significant effect on spherical aberrations for time of 
measurement F (2, 92) = 1.282, p = 0.282 or eye type F (1, 46) = 1.112, p = 0.33. The main results for 
time of measurement after application of liposome spray were F (2, 92) = 1.112, p = 0.33, with no 
significant difference for eye type F (1, 46) = 1.112, p = 0.33. The effect on spherical aberrations for 
the interventions combined was insignificant; F (1.39, 63.77) = 0.836, p = 0.40, Greenhouse-Geisser 
corrected. There was no significant effect for eye type (F1, 46) = 0.781, p = 0.38. 
Instillation of hypromellose drops had no significant effect on coma for time of measurement F 
(1.49, 63.40) = 0.527, p = 0.54 or eye type F (1, 46) = 0.106, p = 0.74. The main results for time of 
measurement after application of liposome spray were F (2, 92) = 0.120, p = 0.887, with no 
significant difference for eye type F (1, 46) = 0.086, p = 0.770. The effect on coma for the 
interventions combined was insignificant; F (1.21, 55.52) = 1.767, p = 0.189, Greenhouse-Geisser 
corrected. There was no significant effect for eye type (F1, 46) = 0.071, p = 0.791. 
 
DISCUSSION 
A third of the ‘dry eye’ group scored 7 in the questionnaire, which only just placed them in to the 
‘dry’ category. There is a strong possibility that the differences between the ‘normal eye’ and ‘dry 
eye’ groups failed to reach statistical significance due to the high proportion of borderline ‘normal 
eyes’ in the ‘dry eye’ group.  The measurement of visual quality immediately after instillation of 
hypromellose drops was found to be significantly worse, in agreement with other studies 
investigating artificial tears [33-35], however, the non-significant result following instillation of the 
hypromellose drops and liposome spray combined was unexpected. This may have been due to 
small variations in drop size or amount of spray applied, however, the same investigator (SM) 
applied all interventions in an attempt to standardise the dosage. Ridder et al. measured the drop 
weight in their study, but concluded that it was unlikely to affect the results [33] so this is unlikely to 
have been a major factor. The timing of the measurements after a blink was another possible source 
of variation; however, the technique used followed established protocol [33]. The results are more 
likely to have been influenced by the psychological factor of having two interventions at the same 
time which may have led to increased blinking or lid squeezing, where excess volume of the drop 
could wash the liposome spray away. The comfort scores, however, were marginally higher for the 
combination of products; the subjects possibly perceiving a larger effect due to ‘more’ intervention, 
although this did not extend to the treatment preferences. The convenience of having a multi-use 
spray which needed no mirror to aid application was a factor commonly cited by subjects when 
choosing their preferred product. The non-significant post hoc tests following a significant result for 
the Friedman analysis of the comfort scores may indicate a Type 1 error; however, it is more likely 
that this reflects a lack of power, particularly in a small sample size. In this study the 60 minute time 
interval to question the issue of comfort may not have been long enough. Furthermore, the 
measurement of aberrometry immediately of installation of the drops and again at 60 minutes may 
not have been sufficient to examine the full influence of on aberrations and certainly a follow-up 
study with more frequent and regular measurements would be warranted. 
Larger differences in higher order aberrations may have been found over an increased pupil 
diameter [36], however, these measurements were meant to reflect visual effects in average indoor 
lighting conditions. The values obtained by different methods of aberrometry have been shown to 
vary with respect to values for deviations in wavefronts. The automatic ‘averaging’ function has also 
been cited as a source for error as this is not an indication of reduced variance between the 
measurements; therefore, recommendations for multiple separate measurements have been made 
[37]. The differences between the dry and normal group did not reach statistical significance at the 
hour time point for any of interventions and there were large standard deviations in the 
measurements. This may be due to fluctuations in accommodation [38, 39], the variable nature of 
the aberrations themselves e.g. local aberrations at the border of the tear film breaking up where 
the slope would be steep; the complex nature of such aberrations would not be well described by 
Zernike modes. Acceptable tolerances for measurement with aberrometry may also mean that the 
error exceeds the differences in total aberrations between the normal and borderline dry eyes [36, 
40].  
Based on Craig’s findings investigating normal eyes [21], it is not unreasonable to expect the effect in 
border-line dry eyes to be more short-lived and a difference to show between the groups at the 60 
minute time mark. It may have been more informative to take measurements more frequently, for 
example every ten minutes, to see if there was a point where there was a difference between dry 
and normal eyes, however, the study was designed to assess the benefit of combining treatments 
and specifically showing a difference between normal and dry eyes at the 60 minute time point, 
which would have been of clinical interest.  
Fluorescein sodium was used to assess corneal staining following the final aberration 
measurements; however, there was no staining in any participants. Ideally it would have been better 
to assess the cornea before treatment, but this would clearly interfere with the results due to the 
established destabilising effect the drug has on the tear film and the invasive nature of the test. 
Other studies have assessed staining on a different day to measurement for inclusion criteria [33, 
34], however, due to the variable nature of the tear film, the method chosen in this study was 
considered to be the most effective representation of the ocular surface at the time of 
measurement. There is also ambiguity regarding what fluorescein staining actually represents and 
particularly whether it really gives a true representation of the integrity of the cornea [6]. 
Combining artificial tear drop and liposome spray treatments for dry eye has not been shown to 
improve or prolong effectivity as measured by aberrometry over a 5mm pupil in dry or normal eyes. 
One application of any ocular lubricant gave a subjective improvement although this could not be 
detected by aberrometry after one hour. This may suggest that in a clinical setting, symptomatic 
patients with no corneal staining could benefit from ocular lubricants for symptomatic relief.  
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Treatment 
Unpreserved hypromellose 
drops 
Unpreserved liposome 
spray 
Combination 
No 
preference 
Subjects 
Normal 66.60% 33.40% 0 0 
Dry 37.60% 50% 8.40% 4% 
 
Table 1 
 
 
Baseline visit Hypromellose Drops Baseline visit Liposome Spray Baseline Visit Combination 
Normal 
Eyes Dry eyes 
P 
value Normal Eyes Dry Eyes 
P 
value Normal Eyes Dry Eyes 
P 
value 
Coma (µm) 
0.105 ± 
0.045 
0.100 ± 
0.050 0.75 
0.085 ± 
0.042 
0.106 ± 
0.048 0.12 
0.090 ± 
0.056 
0.104 ± 
0.057 0.37 
Spherical aberrations (µm) 
0.044 ± 
0.033 
0.036 ± 
0.022 0.34 
0.041 ± 
0.029 
0.039 ± 
0.029 0.87 
0.040 ± 
0.027 
0.058 ± 
0.078 0.36 
Total higher order 
aberrations(µm) 
0.218 ± 
0.078 
0.237 ± 
0.078 0.29 
0.204 ± 
0.075 
0.238 ± 
0.063 0.14 
0.213 ± 
0.091 
0.239 ± 
0.084 0.21 
 
Table 2 
  
Hypromellose drops Liposome spray Hypromellose drops and liposome spray 
Normal Eyes Dry eyes Normal Eyes Dry eyes Normal Eyes Dry eyes 
Baseline After 1 hour Baseline After 1 hour Baseline After 1 hour Baseline After 1 hour Baseline After 1 hour Baseline After 1 hour 
Coma (µm) 
0.105 ± 
0.045 
0.119 ± 
0.115 
0.101 ± 
0.050 
0.107 ± 
0.043 
0.108 ± 
0.047 
0.106 ± 
0.053 
0.107 ± 
0.048 
0.103 ± 
0.047 
0.091 ± 
0.057 
0.089 ± 
0.049 
0.104 ± 
0.058 
0.109 ± 
0.047 
Spherical aberrations (µm) 
0.044 ± 
0.030 
0.040 ± 
0.029 
0.036 ± 
0.022 
0.035 ± 
0.021 
0.041 ± 
0.029 
0.038 ± 
0.029 
0.040 ± 
0.029 
0.035 ± 
0.019 
0.040 ± 
0.027 
0.040 ± 
0.029 
0.058 ± 
0.079 
0.038 ± 
0.023 
Total higher order aberrations(µm) 
0.218 ± 
0.079 
0.213 ± 
0.075 
0.237 ± 
0.078 
0.243 ± 
0.062 
0.204 ± 
0.075 
0.209 ± 
0.082 
0.238 ± 
0.063 
0.243 ± 
0.073 
0.213 ± 
0.091 
0.221 ± 
0.084 
0.239 ± 
0.084 
0.247 ± 
0.084 
Table 3
  
 
Fig. 1. Comfort scores out of 10, before and one hour after treatment (n = 24 for each 
group), where 10 represents the most comfortable (SD indicated). 
Table 1. Treatment preferences for all subjects (n = 24 for each group) 
Table 2. Results of independent t-test for baseline total higher order aberrations between 
normal (n = 24) and dry (n = 24) eyes on each separate visit  
Table 3. Mean and standard deviation for higher order aberrations in normal (n = 24) and 
dry (n = 24) groups for each intervention at baseline and when measured one hour later. 
